Latest Balance Sheet News

Catalyst Metals Limited has secured A$150 million in equity to fund organic growth and exploration across its flagship Plutonic Gold Belt and Bendigo Gold Belt projects. The company aims to nearly double gold production to around 200,000 ounces per annum while reducing costs through strategic acquisitions and infrastructure leverage.

Catalyst Metals has raised $150 million through an institutional placement to fund growth projects at its Plutonic Gold Belt and bolster its balance sheet. This capital injection positions the company to expand production and advance exploration without financial strain.

Bendigo and Adelaide Bank reported a 7.8% decline in cash earnings for 3Q25, reflecting lower other income and a slight dip in net interest income, while completing its Rural Bank system migration.

Oceania Healthcare Limited reported a robust FY25 with a 9.2% rise in sales volume and a 5.8% increase in comprehensive income, underpinned by a successful $500 million debt refinancing and operational enhancements.

EQ Resources Limited has successfully raised $18.8 million through a share placement, complemented by a $3 million Share Purchase Plan, to fund its tungsten mining projects and reduce debt.

SKS Technologies has delivered a robust first half in 2025, showcasing strong revenue growth and a burgeoning project pipeline, underpinned by zero debt and strategic expansion in data centres and traditional electrical services.

Perenti’s African Underground Mining Services has locked in a five-year, A$1 billion contract to provide underground mining services at Ghana’s Obuasi Gold Mine, reinforcing its strategic partnership with AngloGold Ashanti.

Australian Agricultural Company Limited (AACo) reported a 14% rise in operating profit to $58.4 million for FY25, driven by increased sales volumes and disciplined cost control despite challenging market conditions. The company also marked a significant reduction in statutory loss, signaling improved financial resilience.

Australian Agricultural Company Limited (AACo) has reported a robust turnaround in its FY25 results, with significant gains in revenue and profitability driven by higher sales volumes and improved operational efficiency.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

AFT Pharmaceuticals reported a 6% increase in revenue to NZ$208 million for the year ending March 2025, but net profit fell 23%, prompting a modest final dividend declaration.

Elixinol Wellness Limited is poised to lift its trading suspension on May 22, 2025, following a significant announcement regarding its financing and capital structure.